News
CLIFF
0.090
NaN%
--
Cordlife Group Faces Legal Claims Over Damaged Cord Blood Units
TipRanks · 12/02/2025 14:16
Cordlife Group Announces Board Restructuring
TipRanks · 12/02/2025 13:18
Cordlife Faces Regulatory Changes in Cord Blood Banking Licence
TipRanks · 12/01/2025 13:18
Cordlife Group Announces Board Restructuring
TipRanks · 10/30/2025 13:46
Cordlife Submits Representations to MOH Amid License Suspension Concerns
TipRanks · 10/27/2025 15:12
Cordlife Group Addresses Media Inaccuracies on License Suspension
TipRanks · 10/21/2025 04:42
Cordlife Granted Extension for License Representation Amid Operational Halt
Barchart · 10/13/2025 19:14
Cordlife Faces Potential License Suspension and Financial Challenges
Barchart · 10/06/2025 20:14
Cordlife Faces License Suspension Over Regulatory Non-Compliance
TipRanks · 10/01/2025 14:45
Weekly Report: what happened at CLIFF last week (0908-0912)?
Weekly Report · 09/15/2025 11:26
Weekly Report: what happened at CLIFF last week (0901-0905)?
Weekly Report · 09/08/2025 11:29
Weekly Report: what happened at CLIFF last week (0825-0829)?
Weekly Report · 09/01/2025 11:23
Weekly Report: what happened at CLIFF last week (0818-0822)?
Weekly Report · 08/25/2025 11:35
Weekly Report: what happened at CLIFF last week (0811-0815)?
Weekly Report · 08/18/2025 11:26
Cordlife Clarifies Enhanced Package for Affected Customers
TipRanks · 08/14/2025 16:13
Cordlife Group Faces Legal Challenges Over Cord Blood Storage
TipRanks · 08/14/2025 16:13
Weekly Report: what happened at CLIFF last week (0804-0808)?
Weekly Report · 08/11/2025 11:35
Weekly Report: what happened at CLIFF last week (0728-0801)?
Weekly Report · 08/04/2025 11:37
More
Webull provides a variety of real-time CLIFF stock news. You can receive the latest news about Cordlife Group through multiple platforms. This information may help you make smarter investment decisions.
About CLIFF
Cordlife Group Limited is a Singapore-based company that owns cord blood banks across Asia, including Hong Kong, Indonesia, the Philippines, India, and Malaysia. The Company's principal activities involve investment holding and the provision of cord blood banking services. Its segments include Banking and Diagnostics. The Banking segment comprises of the banking of samples such as cord blood, cord lining and cord tissue. Cord blood, cord lining and cord tissue are collected, processed, and stored in the various laboratories. The Diagnostics segment comprises diagnostic testing such as non-invasive prenatal testing service, newborn metabolic screening, newborn genetic screening, and pediatric vision screening services. Its subsidiaries include Cordlife (Hong Kong) Limited, Cordlife Stem Cell Technology Limited, Healthbaby Biotech (Hong Kong) Co., Limited, Cordlife Technologies Pte. Ltd., CS Cell Technologies Pte. Ltd., Stemlife Berhad, and Shanghai Cordlife Biomedical Research Co., Ltd.